Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 18/20 | 0.79 |
| ▸ | WNT1 | P04628 | 9/20 | 0.79 |
| ▸ | CLK2 | P49760 | 8/20 | 0.72 |
| ▸ | CLK3 | P49761 | 7/20 | 0.72 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804420 | 0.94 | DYRK1A (0.72) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL20348626 | 0.93 | DYRK1A (0.70) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL14792780 | 0.93 | DYRK1A (0.73) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL14792150 | 0.93 | DYRK1A (0.73) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL14792061 | 0.93 | DYRK1A (0.82) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL25728222 | 0.93 | CLK2 (0.73) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL14803955 | 0.91 | DYRK1A (0.70) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL14803978 | 0.91 | DYRK1A (0.67) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL17364524 | 0.90 | DYRK1A (0.68) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL14792216 | 0.90 | DYRK1A (0.68) | DYRK1AWNT1CLK2CLK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-05 | — | — | US | disclosed |
| US-9221793-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | SAMUMED, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185343-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, CTNNB1, WNT3A | DYRK1A 227/4885WNT1 4/4885CLK2 1389/4885 |
| US-11684615-B2 | Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT3, WNT3A, WNT1 | DYRK1A 167/4885WNT1 3/4885CLK2 1376/4885 |
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, WNT1, WNT3A | DYRK1A 733/4885WNT1 2/4885CLK2 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.